Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at the Royal Lancaster in London, UK. This award follows shortly after securing ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony last month in London and ‘Best ADC Platform Technology’ at the World ADC Conference 2022 in September.
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at the Royal Lancaster in London, UK. This award follows shortly after securing ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony last month in London and ‘Best ADC Platform Technology’ at the World ADC Conference 2022 in September.
The Scrip Award recognizes the successful track record of Synaffix’s Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space. The BD Team has been instrumental in the signing of six licensing deals during the award qualifying period with deal values around $500 million to $1 billion. These include agreements with Mersana ($1b), Genmab ($415m), Macrogenics ($586m), Kyowa Kirin (value not disclosed) and Emergence Therapeutics ($360m). Further, deal-making activities to date have resulted in five ADCs that have entered clinical development and resulted in aggregate potential deal value exceeding $3.6 billion across all its partnerships.
Anthony DeBoer, Vice President of Business Development at Synaffix, said: “We are honored to receive this award and be recognized by the independent judging panel of industry leaders and experts for our partnering activities in the ADC space. To date, we have established 10 partnerships with major biotech and pharma companies, 17 ADCs have resulted from our deals and 5 ADC programs have entered clinical development. Shifting the cancer treatment landscape away from chemotherapy, towards a targeted approach for each disease is a major undertaking, and we are highly motivated to contribute to these efforts using our innovative technology. We would like to thank our growing family of biotech and pharma partners for their trust and support over the years and look forward to building additional partnerships aimed at delivering best-in-class targeted cancer therapeutics for patients in need.”
Technology out-licensing is a core focus of the corporate strategy at Synaffix, leveraging its proprietary platform to deliver best-in-class targeted cancer therapeutics from partner antibodies. The Company’s ADC technology platform enables a rapid timeline to clinic due to the established supply chain of technology components. Granted patents covering Synaffix’s technology provide end-to-end protection of the technology as well as the resulting products through at least 2035. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals.
